GLP1R and diabetes mellitus: 39345822 39345822 Stefanou MI, Palaiodimou L, Theodorou A et al (2024) Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP‐1 RAs or the dual GIP/GLP‐1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.